What does the new Alzheimer's Aduhelm (aducanumab) drug do?

The new Alzheimer's drug, Aduhelm (generic name: aducanumab), is a monoclonal antibody that targets beta-amyloid, a protein that forms sticky plaques in the brains of people with Alzheimer's disease. The theory behind Aduhelm is that by removing beta-amyloid from the brain, it may slow or halt the progression of Alzheimer's disease. The drug is given through monthly infusions and is intended for people with early-stage Alzheimer's disease who have mild cognitive impairment or mild dementia.

Aduhelm was approved by the U.S. Food and Drug Administration (FDA) in June 2021, making it the first drug to be approved for Alzheimer's disease since 2003. The approval was controversial because some experts questioned the drug's effectiveness and raised concerns about its high cost and potential side effects.

Since its approval, Aduhelm has generated significant public debate and criticism. Some experts have raised concerns about the limited evidence of the drug's effectiveness and the potential risks of brain swelling and bleeding. Additionally, the high cost of the drug (estimated at $56,000 per year) has led to questions about its affordability and accessibility for patients.

Despite these concerns, Aduhelm has been hailed as a potential breakthrough in the treatment of Alzheimer's disease, a devastating condition that affects millions of people worldwide. Ongoing research and clinical trials will help to further understand the safety and effectiveness of the drug and its potential impact on the lives of people with Alzheimer's disease.